Rockwell Medical logo
Rockwell Medical RMTI
$ 0.79 -2.06%

Quarterly report 2026-Q1
added 05-07-2026

report update icon

Rockwell Medical Balance Sheet 2011-2026 | RMTI

Annual Balance Sheet Rockwell Medical

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Net Debt

-730 K -5.62 M 691 K -1.06 M 7.29 M -47.5 M -7.76 M -22.7 M -8.41 M -17.2 M -31.2 M -65.8 M 8.34 M -4.71 M -5.71 M - - -

Long Term Debt

8.83 M 8.47 M 8.29 M 7.56 M 13.2 M - - - - - - - 17.9 M - - - - -

Long Term Debt Current

1.16 M 1.57 M 1.38 M 1.48 M 7.38 M - 1.49 M - - - - - 2.31 M - - - - -

Total Non Current Liabilities

- - - - - - 11.6 M 12.1 M 16.7 M 20.1 M 17.4 M 19.5 M 17.9 M - 2.28 K - - -

Total Current Liabilities

9.58 M 14.1 M 16.6 M 17.7 M 21 M 12.8 M 12.4 M 13.2 M 9.14 M 10.1 M 8.09 M 9.8 M 17.8 M 27 M 13.7 M 6.42 M - -

Total Liabilities

20.2 M 26.6 M 30.9 M 32.5 M 46 M 43.6 M 24 M 25.3 M 25.9 M 30.2 M 25.5 M 29.3 M 35.8 M 27 M 13.7 M - - -

Deferred Revenue

- 46 K 46 K 1.73 M 2.17 M 2.18 M 2.29 M 2.32 M 205 K 77.2 K 265 K 184 K 208 K 135 K - - - -

Retained Earnings

-403 M -398 M -397 M -389 M -370 M - -307 M -272 M -240 M -214 M -195 M -180 M -159 M -110 M -56 M -34.5 M - -

Total Assets

57.1 M 59.2 M 52.2 M 46.6 M 48.6 M 77.7 M 44.3 M 52.6 M 58.8 M 83.2 M 87.8 M 98 M 36.4 M 17 M 31.9 M 37 M - -

Cash and Cash Equivalents

10.7 M 15.7 M 8.98 M 10.1 M 13.3 M 48.7 M 11.8 M 22.7 M 8.41 M 17.2 M 31.2 M 65.8 M 11.9 M 4.71 M 5.72 M 12.3 M 23 M 5.6 M

Book Value

37 M 32.6 M 21.3 M 14.1 M 2.54 M 34.2 M 20.3 M 27.3 M 32.9 M 53 M 62.3 M 68.7 M 596 K -9.96 M 18.2 M 37 M - -

Total Shareholders Equity

37 M 32.6 M 21.3 M 14.1 M 2.54 M 34.2 M 20.3 M 27.3 M 32.9 M 53 M 62.3 M 68.7 M 596 K -9.96 M 18.2 M 30.5 M 29.3 M 11.8 M

All numbers in USD currency

Quarterly Balance Sheet Rockwell Medical

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

8.21 M 8.74 M 8.65 M 8.56 M 8.47 M 8.38 M 8.3 M 8.26 M 8.29 M 3.33 M 4.74 M 6.15 M 7.56 M 8.96 M 10.4 M 11.8 M 13.2 M 14.1 M - 21 M 20.9 M 20.9 M 20.9 M 20.9 M - - - - - - - - - - - - - - - - - - - - - 12.1 M 14.5 M 16.2 M 17.9 M 17.9 M 17.9 M 17.9 M - - - - - - - -

Total Liabilities

21.6 M 20.5 M 22.2 M 22.4 M 26.6 M 27.9 M 29.5 M 30.1 M 30.9 M 31.1 M 28.5 M 27.9 M 32.5 M 38 M 39 M 42.2 M 46 M 47.6 M 45.5 M 43.3 M 43.6 M 43.6 M 43.6 M 43.6 M 24 M 24 M 24 M 24 M 25.3 M 25.3 M 25.3 M 25.3 M 25.9 M 25.9 M 25.9 M 25.9 M - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - 46 K 46 K 46 K 46 K 46 K 46 K 259 K 259 K 1.73 M 2.16 M 2.17 M 2.16 M 2.17 M 2.18 M 2.17 M 2.17 M 2.18 M 2.18 M 2.18 M 2.18 M 2.23 M 2.23 M 2.23 M 2.23 M 2.25 M 2.25 M 2.25 M 2.29 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-405 M -402 M -401 M -399 M -398 M -397 M -399 M -399 M -397 M -396 M -394 M -391 M -389 M -386 M -382 M -377 M -370 M -361 M -354 M -345 M -337 M -337 M -337 M -337 M -307 M -307 M -307 M -307 M -272 M -272 M -272 M -272 M -240 M -240 M -240 M -240 M -214 M -214 M -214 M -214 M -195 M -195 M -195 M -195 M -180 M -180 M -180 M -180 M -159 M -159 M -159 M -159 M -110 M -110 M -110 M -110 M -56 M -56 M -56 M -56 M

Total Assets

57.4 M 57.5 M 52.6 M 54 M 59.2 M 57.1 M 53 M 50.7 M 52.2 M 52.6 M 38 M 40.5 M 46.6 M 54.2 M 59.1 M 37.4 M 48.6 M 58.7 M 63.7 M 69.4 M 77.7 M 77.7 M 77.7 M 77.7 M 44.3 M 44.3 M 44.3 M 44.3 M 52.6 M 52.6 M 52.6 M 52.6 M 58.8 M 58.8 M 58.8 M 58.8 M 83.2 M 83.2 M 83.2 M 83.2 M 87.8 M 87.8 M 87.8 M 87.8 M 98 M 98 M 98 M 98 M 36.4 M 36.4 M 36.4 M 36.4 M 17 M 17 M 17 M 17 M 31.9 M 31.9 M 31.9 M 31.9 M

Cash and Cash Equivalents

9.61 M 13.6 M 12.5 M 11.4 M 15.7 M 12.3 M 11.9 M 6.64 M 8.98 M 7.76 M 8.96 M 10.9 M 10.1 M 13 M 30.8 M 9.91 M 13.3 M 23.4 M 32.4 M 35.7 M 48.7 M 48.7 M 48.7 M 48.7 M 11.8 M 11.8 M 11.8 M 11.8 M 22.7 M 22.7 M 22.7 M 22.7 M 8.41 M 8.41 M 8.41 M 8.41 M 17.2 M 17.2 M 17.2 M 17.2 M 31.2 M 31.2 M 31.2 M 31.2 M 65.8 M 65.8 M 65.8 M 65.8 M 11.9 M 11.9 M 11.9 M 11.9 M 4.71 M 4.71 M 4.71 M 4.71 M 5.72 M 5.72 M 5.72 M 5.72 M

Book Value

35.9 M 37 M 30.4 M 31.5 M 32.6 M 29.1 M 23.5 M 20.6 M 21.3 M 21.5 M 9.53 M 12.5 M 14.1 M 16.1 M 20.1 M -4.81 M 2.54 M 11.1 M 18.2 M 26.2 M 34.2 M 34.2 M 34.2 M 34.2 M 20.3 M 20.3 M 20.3 M 20.3 M 27.3 M 27.3 M 27.3 M 27.3 M 32.9 M 32.9 M 32.9 M 32.9 M 83.2 M 83.2 M 83.2 M 83.2 M 87.8 M 87.8 M 87.8 M 87.8 M 98 M 98 M 98 M 98 M 36.4 M 36.4 M 36.4 M 36.4 M 17 M 17 M 17 M 17 M 31.9 M 31.9 M 31.9 M 31.9 M

Total Shareholders Equity

35.9 M 37 M 30.4 M 31.5 M 32.6 M 29.1 M 23.5 M 20.6 M 21.3 M 21.5 M 9.53 M 12.5 M 14.1 M 16.1 M 20.1 M -4.81 M 2.54 M 11.1 M 18.2 M 26.2 M 34.2 M 34.2 M 34.2 M 34.2 M 20.3 M 20.3 M 20.3 M 20.3 M 27.3 M 27.3 M 27.3 M 27.3 M 32.9 M 32.9 M 32.9 M 32.9 M 53 M 53 M 53 M 53 M 62.3 M 62.3 M 62.3 M 62.3 M 68.7 M 68.7 M 68.7 M 68.7 M 596 K 596 K 596 K 596 K -9.96 M -9.96 M -9.96 M -9.96 M 18.2 M 18.2 M 18.2 M 18.2 M

All numbers in USD currency

Balance Sheet is a fundamental financial report of Rockwell Medical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Drug manufacturers

Issuer Price % 24h Market Cap Country
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.87 6.53 % $ 87.2 M usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Cronos Group Cronos Group
CRON
$ 2.74 0.37 % $ 1.05 B canadaCanada
Harrow Health Harrow Health
HROW
$ 33.0 0.12 % $ 1.21 B usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 2.66 - $ 337 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 23.35 -0.55 % $ 1.08 B usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 5.47 0.37 % $ 2 B canadaCanada
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 1.04 -2.8 % $ 112 M canadaCanada
Tilray Tilray
TLRY
$ 5.29 -3.11 % $ 3.27 B canadaCanada
Solid Biosciences Solid Biosciences
SLDB
$ 6.62 1.85 % $ 579 M usaUSA
Aurora Cannabis Aurora Cannabis
ACB
$ 3.46 -2.81 % $ 190 M canadaCanada
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.1 3.77 % $ 1.37 M usaUSA
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
OrganiGram Holdings OrganiGram Holdings
OGI
$ 1.12 -0.88 % $ 107 M canadaCanada
Evolus Evolus
EOLS
$ 6.09 -5.58 % $ 393 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.45 -1.36 % $ 3.37 M canadaCanada
Emergent BioSolutions Emergent BioSolutions
EBS
$ 8.45 0.96 % $ 433 M usaUSA
Veru Veru
VERU
$ 2.35 5.86 % $ 34.4 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
cbdMD cbdMD
YCBD
$ 0.76 -2.32 % $ 3.06 M usaUSA
Assertio Holdings Assertio Holdings
ASRT
$ 23.44 0.3 % $ 150 M usaUSA
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 7.04 -2.36 % $ 278 M usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
SCYNEXIS SCYNEXIS
SCYX
$ 0.73 3.0 % $ 36.5 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Viatris Viatris
VTRS
$ 16.65 1.15 % $ 19.4 B usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.76 -0.29 % $ 3.26 M chinaChina
TherapeuticsMD TherapeuticsMD
TXMD
$ 2.12 0.47 % $ 24.5 M usaUSA